(R)-(-)-1-Aminoindane CAS 10277-74-4 Puritas >98.0% (GC) EE >98.0%

Description:

Chemical Name: (R)-(-)-1-Aminoindane

CAS: 10277-74-4

Puritas: >98.0% (GC)

Chiral Puritas (ee): >98.0%

Aspectus: hyalina vel Yellow Liquid

Contactus: Dr

Mobile/Wechat/Whatsapp: +86-15026746401

E-Mail: alvin@ruifuchem.com

Mitte ad nos inscriptio

Product Detail

Product Tags

Descriptio:

Shanghai Ruifu Chemical Co., Ltd. est primarius fabricae et elit (R)-(-)-1-Aminoindane (CAS: 10277-74-4) magna qualitate.CoA praebere possumus, totius orbis partus, parvas et parvas quantitates in promptu habentes.Si interesse in hoc facto, singula informationes mittas mitte nobis numerum CAS, nomen productum, quantitatem nobis.Please contact: alvin@ruifuchem.com

Chemical Properties:

Nomen chemicum	(R)-(-)-1-Aminoindane
Synonyma	(R) -1-Aminoindane;(R)-(-)-1-Indanamine;(1R)-Indan-1-Amine;(R) -1-Indanylamin;(R)-2,3-Dihydro-1H-Inden-1-Amine;(1R)-2,3-Dihydro-1H-Inden-1-Amine;(R)-2,3-Dihydro-1-Indenamine
CAS Number	10277-74-4
CATTUS Number	RF-CC358
Stock Status	In Stock, Productio Ascendite ad Tons
Formulae hypotheticae	C9H11N
M. Pondus	133.19
Liquescens punctum	15℃ (lit.)
Ferveret	96.0~97.0/8 mmHg (lit.)
Density	1.038 g/mL ad 25℃(lit.)
Index refractivus n20/D	1.562 (lit.)
Sensitiva	Aer Sensitiva
Solubilitas	Solutum in Methanol.Non Miscible aut difficile miscere in aqua
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Aspectus	Hyalina vel Yellow Liquid
Puritas / Analysis Methodus	>98.0% (GC)
Chiral Purity (EE)	>98.0%
Imprimis rotationis [α]20/D	-18.0° ~ -15.0° (C=1.5% in MeOH)
Totalis immunditias	<2.00%
Infrared Imaginis	Conformat ut Structure
Proton NMR Spectrum	Conformat ut Structure
Test Standard	Enterprise Standard
Consuetudinem	Chiral Compositum;Pharmaceutical intermedia

Sarcina & Repono:

sarcina: Fluorinated Utrem, 25kg/Drum, vel secundum exigentiam mos

Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine et humore

commoda:

Satis capacitas: sufficientes facilities et technici

Professional Service: One stop acquireing service

Altera Package: Custom sarcina ac titulus praesto

Ieiunium Delivery: Si intra stirpem, tres dies partus praestatur

Supple firmum: Esse rationabile stirpe

Technical Support: Technology solution praesto

Custom Synthesis Service: Range from P. to kilos

High Quality: Constitutus ratio completa qualitas certitudinis

FAQ:

Quam mercari?Quaeso contactumDr. Alvin Huang: sales@ruifuchem.com or alvin@ruifuchem.com

15 Years Experience?Plus quam XV annos experientiae habemus in fabricando et exportando amplis intermediis pharmaceuticis vel alchimicis pharmaceuticis amplis.

Mercatus principalis?Vendere mercatum domesticum, Americam septentrionalem, Europam, Indiam, Coream, Iaponicam, Australiam etc.

Commodi?Superior qualitas, parabilis pretium, officia professionalia et subsidia technica, ieiunium partus.

Qualitasfides?Qualitas strictioris temperantiae ratio.Pro instrumento analysi professionali includuntur NMR, LC-MS, GC, HPLC, ICP-MS, UV, IR, OR, KF, ROI, LOD, MP, Claritas, Solubilitas, Microbialis limes test, etc.

Exempla?Pleraque producta praebent exempla gratuita pro qualitate aestimationis, sumptus naviculas a clientibus solvendos.

Factory Audit?Factory audit gratissimum.Quaeso ante constitutum.

MOQ?Nec MOQ.Parvus ordo placet.

Tempus adferendi? Si intus prosapia, tres dies partus praestatur.

Transportatio?Per Express (FedEx, DHL), ab Air, per Mare.

Documenta?Post servitium venditionis: COA, MOA, ROS, MSDS, etc. praeberi possunt.

Consuetudo Synthesis?Consuetudo synthesis officia praebere potest ad optimas investigationes tuas necessitates aptandas.

Pensio conditio?Proforma cautionis primum post confirmationem ordinis mittetur, informationes nostrae ripae inclusas.Payment by T/T (Telex Transfer), PayPal, Western Union, etc.

Applicatio:

(R)-(-)-1-Aminoindane (CAS: 10277-74-4) immunditia vel media Rasagiline (CAS: 136236-51-6) vel Mesylate Rasagiline (CAS: 161735-79-1).Mesylate Rasagiline oxydatum B (MAO-B) inhibitoris impositum validum et selectivum monoamine immedicabile anno 2005 in Israele a Teva sicut monotherapia in aegris cum morbo primo Parkinson et adiuvante curationem in morbo moderato-moderato.Lundbeck medicamentum per Europam mercatus est.Rasagiline in periodo II tentationum clinicarum apud Teva et Eisai est ad curationem generis dementiae Alzheimer.